Bunnage Mark E.
CIK 0002100735
EVP, Chief Scientific Officer
Filings
5
Latest May 19, 2026
Issuers covered
1
Showing
5 of 5
Page 1
Track record
4 of 5 open-market trades scored (80% price coverage) - 1 issuer without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 4 | 75% | +4.0% | +3.8% | +10.3% | -1.8% |
| 90 days | 4 | 100% | +7.2% | +8.1% | +9.8% | +2.8% |
| 180 days | - | - | - | - | - | - |
| 365 days | - | - | - | - | - | - |
Issuers
Companies where Bunnage Mark E. has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc / Ma | 5 | May 19, 2026 |
All filings
5 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|